BIOMAT Database Logo BIOMAT Database Logo

Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. 1995

R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Department of Infectious Diseases, University of Genoa, Italy.

Thirty-five children with chronic HBV infection, HBV-DNA and eAg serum positivity, and HBcAg in liver tissue were treated with lymphoblastoid human interferon alpha with (16 cases) or without (19 cases) prednisolone pretreatment. The patients were double-blind randomized to receive steroid or placebo for 4 weeks, followed after 2 weeks by 5 or 10 MU/m2 interferon for 12 weeks. The e anti-e seroconversion rate reached 48%, which is much higher than the spontaneous seroconversion rate. The influence of "prednisolone priming" was not statistically significant. HBeAg clearance was similar in both groups (44% after prednisolone/interferon and 53% after interferon alone). The response to either treatment did not correlate with the pretreatment serum transaminase. HBV-DNA or degree of histological activity. Interferon was well tolerated, the side effects being less severe than in adults, and never led to suspension of the treatment.

UI MeSH Term Description Entries
D008297 Male Males
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection

Related Publications

R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.
April 1996, Hepatology (Baltimore, Md.),
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Recombinant interferon-alpha-2A with or without steroid pretreatment in children with chronic hepatitis B.
January 1998, The Turkish journal of pediatrics,
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B.
May 1987, Gut,
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B.
January 1986, Journal of hepatology,
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
[Treatment of chronic hepatitis B with lymphoblastoid alpha interferon].
November 1989, Medicina clinica,
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis.
January 1989, BMJ (Clinical research ed.),
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection.
September 1989, BMJ (Clinical research ed.),
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
January 1998, Lancet (London, England),
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C.
July 2001, Journal of viral hepatitis,
R Giacchino, and J Main, and A Timitilli, and G Giambartolomei, and F Facco, and C Cirillo, and M R Jacyna, and M G Brook, and F Callea, and P Kariayannis
Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole.
November 1992, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!